Filipijnen - Engels - FDA (Food And Drug Administration)

novartis healthcare philippines, inc.; distributor: sandoz philippines corporation - vildagliptin - tablet - 50 mg

Filipijnen - Engels - FDA (Food And Drug Administration)

novartis healthcare philippines, inc.; distributor: sandoz philippines corporation - vildagliptin , metformin hydrochloride - film-coated tablet - 50mg/1g

Filipijnen - Engels - FDA (Food And Drug Administration)

novartis healthcare philippines, inc.; distributor: sandoz philippines corporation - vildagliptin , metformin hydrochloride - film-coated tablet - 50 mg/500 mg

Filipijnen - Engels - FDA (Food And Drug Administration)

novartis healthcare philippines, inc.; distributor: sandoz philippines corporation - oxcarbazepine - film-coated tablet - 600 mg

Israël - Engels - Ministry of Health

novartis israel ltd - inclisiran as sodium - solution for injection - inclisiran as sodium 189 mg/ml - inclisiran - leqvio is indicated in adults with primary hypercholesterolaemia (heterozygous familial and non familial) or mixed dyslipidaemia, as an adjunct to diet:• in combination with a statin or statin with other lipid lowering therapies in patients unable to reach ldl c goals with the maximum tolerated dose of a statin, or• alone or in combination with other lipid lowering therapies in patients who are statin intolerant, or for whom a statin is contraindicated.

Australië - Engels - Department of Health (Therapeutic Goods Administration)

novartis pharmaceuticals australia pty ltd - inclisiran, quantity: 284 mg - injection, solution - excipient ingredients: sodium hydroxide; phosphoric acid; water for injections - leqvio is indicated as an adjunct to diet and exercise to reduce low-density lipoprotein cholesterol (ldl-c) in adults with heterozygous familial hypercholesterolaemia, atherosclerotic cardiovascular disease, or at high risk of a cardiovascular event:,? in combination with a statin or statin with other lipid-lowering therapies in patients unable to reach ldl-c goals with the maximum tolerated dose of a statin or,,? alone or in combination with other lipid-lowering therapies in patients who are statin-intolerant.

Filipijnen - Engels - FDA (Food And Drug Administration)

for: novartis pharma ag; importer: novartis healthcare philippines, inc. - everolimus - dispersible tablet - 2mg

Filipijnen - Engels - FDA (Food And Drug Administration)

for: novartis pharma ag; importer: novartis healthcare philippines, inc. - everolimus - dispersible tablet - 3mg

Filipijnen - Engels - FDA (Food And Drug Administration)

for: novartis pharma ag; importer: novartis healthcare philippines, inc. - everolimus - dispersible tablet - 5mg

Europese Unie - Engels - EMA (European Medicines Agency)

novartis europharm limited - inclisiran - hypercholesterolemia; dyslipidemias - lipid modifying agents - leqvio is indicated in adults with primary hypercholesterolaemia (heterozygous familial and non-familial) or mixed dyslipidaemia, as an adjunct to diet:in combination with a statin or statin with other lipid-lowering therapies in patients unable to reach ldl-c goals with the maximum tolerated dose of a statin, oralone or in combination with other lipid-lowering therapies in patients who are statin-intolerant, or for whom a statin is contraindicated.